FDA approves second monoclonal antibody treatment for early Alzheimer’s disease
By
Kristen Fischer
Jul 02, 2024
The US Food and Drug Administration (FDA) approved a second monoclonal antibody treatment for for early Alzheimer’s on Tuesday. Eli Lilly’s Kisunla (donanemab), which has proven to slow the disease...
Clinical briefs for Thursday, May 16
By
Kristen Fischer
May 15, 2024
Study: Sleep apnea severity linked to verbal memory decline … Test ties mobility to cognitive function … Spotting osteosarcopenia in heart valve operation patients could predict post-surgical death...
CMS must allow nursing homes to treat neuropsychiatric symptoms of Alzheimer’s
By
Sue Peschin
Chad Worz
Jan 09, 2024
As we start 2024 anew and recover from family-filled holidays, we may have been reminded that celebrations often serve double duty as an informal assessment of health and well-being — including neuropsychiatric...
Clinical briefs for Tuesday, Oct. 3
By
Kristen Fischer
Oct 03, 2023
WHO: Switch back to trivalent flu shots … Vascular cells needed to form long-term memories … Radiation could treat inoperable kidney tumors … “Expired” COVID-19 tests may still be OK, feds say...
Study questions fish oil claims, popularity
By
Kristen Fischer
Aug 24, 2023
One in every five adults aged more than 60 years takes fish oil supplements, despite many warnings that they have no benefit for heart health. A new study sheds light on what the product labels say that...
FDA greenlights first home COVID test with traditional premarket review
By
Alicia Lasek
Jun 07, 2023
The Cue COVID-19 Molecular Test is the first at-home COVID-19 test to be granted marketing authorization outside of emergency use authorities, representing a new era of consumer access to diagnostic tests,...
Providers call for broader antipsychotic exclusions to help reduce schizophrenia diagnoses
By
Kimberly Marselas
Mar 31, 2023
Providers and quality experts are questioning why the agency hasn’t done more to review its quality measure for antipsychotic drug use.
FDA to withdraw certain drug-related guidances with end of PHE
By
Alicia Lasek
Mar 14, 2023
The Food and Drug Administration has issued a notice detailing which COVID-19-related guidances will expire when the public health emergency ends as scheduled on May 11, and which guidances will remain...
Lawmakers push to keep ‘ineffective’ new opioids from market
By
Alicia Lasek
Mar 08, 2023
Congressional lawmakers have renewed efforts to give the Food and Drug Administration more power to deny drug applications for opioids that are not proven clinically superior to and lower risk than currently...
FDA no longer requires positive COVID-19 test to prescribe Paxlovid, Lagevrio
By
Alicia Lasek
Feb 01, 2023
The FDA on Wednesday made it easier for clinicians to prescribe these antiviral drugs in cases where transmission is evident and the patient is at high risk of severe illness.